NCCN Guidelines Updates: Management of Prostate Cancer

Restricted access

Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer.

Correspondence: James L. Mohler, MD, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY 14263. Email: james.mohler@roswellpark.org; and Emmanuel S. Antonarakis, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, MD 21287. Email: eantona1@jhmi.edu
  • 1.

    Aghazadeh MA, Frankel J, Belanger M, . National Comprehensive Cancer Network favorable intermediate-risk prostate cancer – is active surveillance appropriate? J Urol 2018;199:11961201.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Messing EM, Manola J, Yao J, . Immediate versus deferred androgen deprivation treatment in patients with node-positive cancer after radical prostatectomy and pelvic lymphadenopathy. Lancet Oncol 2006;7:472479.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Dong Z, Wang H, Xu M, . Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis. Aging Male 2015;18:233237.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Hussain M, Tangen CM, Berry DL, . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;268:13141325.

  • 5.

    Boevé LM, Hulshof MC, Vis AN, . Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomized clinical trial: data from the HORRAD trial. Eur Urol 2019;75:410418.

    • Search Google Scholar
    • Export Citation
  • 6.

    Parker CC, James ND, Brawley CD, . Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet 2018;392:23532366.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Fizazi K, Shore N, Tarnmela T, . Darolutamide in non-metastatic, castration-resistant prostate cancer [published online February 21, 2019]. N Engl J Med, doi: 10.1056/NEJMoa1815671

    • Search Google Scholar
    • Export Citation
  • 8.

    Marshall CH, Fu W, Wang H, . Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis 2019;22:5965.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Schweizer MT, Antonarakis ES, Bismar TA, . Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. [published online April 18, 2019]. J Clin Oncol Precis Oncol, doi: 10.1200/PO.18.00327

    • Search Google Scholar
    • Export Citation
  • 10.

    Abida W, Cheng ML, Armenia J, . Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade [published online December 27, 2018]. JAMA Oncol, doi: 10.1001/jamaoncol.2018.5801

    • Search Google Scholar
    • Export Citation
  • 11.

    Antonarakis ES, Shaukat F, Isaacsson Velho P, . Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Oncol 2019;75:378382.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 5640 4542 242
PDF Downloads 1482 1047 53
EPUB Downloads 0 0 0